Drug Discovery

Bristol Myers Squibb to buy clinical-stage protein engineering firm Forbius

Bristol Myers Squibb (BMS) has signed an agreement to acquire clinical-stage protein engineering company Forbius for an undisclosed sum.

6000TOCi Sensor

Continuous monitoring provides a real-time data advantage over batch or non-continuous methods of total organic carbon (TOC) measurement.

AbCellera acquires OrthoMab bispecific platform from Dualogics

AbCellera announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics).

J&J to acquire Momenta Pharmaceuticals for $6.5bn

Johnson & Johnson (J&J) has agreed to acquire Momenta Pharmaceuticals, a Massachusetts-based biotech company focused on immune-mediated diseases, in an all-cash deal worth around $6.5bn.

Europe’s largest initiative launches to accelerate therapy development for Covid-19

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.

BOLD-100 significantly outperforms remdesivir head-to-head in SARS-CoV-2 model

Bold Therapeutics, a clinical-stage biopharmaceutical company, recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral.

BMS signs $475m deal with Dragonfly Therapeutics for IL-12 programme

Bristol Myers Squibb (BMS) has agreed to acquire the global exclusive licensing rights to interleukin-12 (IL-12), an investigational immunotherapy programme from Dragonfly Therapeutics, in a deal worth more than $475m.

Gilead, Tango expand collaboration on targeted immuno-oncology treatments

Biopharmaceutical company Gilead Sciences has expanded its strategic oncology collaboration with biotechnology company Tango Therapeutics.

New Edition of NSF’s Health Sciences Journal Now Live

This edition of the health sciences Journal is about hope and optimism, and how we must rethink our ways of working.